Want to see SE:EGTX full AI Analyst Report?
EGTX Stock Chart & Stats
kr8.04
kr0.04(0.50%)
―
--
Day’s Range― - ―
52-Week Rangekr3.63 - kr8.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)792.52K
Market Cap
kr3.72B
Enterprise Valuekr2.34K
Total Cash (Recent Filing)kr378.40M
Total Debt (Recent Filing)kr68.80M
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Nov 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,947,240
10 Day Avg. Volume1,042,665
30 Day Avg. Volume792,519
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr23.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.43
Revenue Forecast (FY)kr396.66M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTTM revenue reached 66.1M with 39.45% growth, indicating stronger revenue generation. Sustained top-line expansion could gradually improve operating leverage, although the company remains loss-making.
Moderate LeverageDebt-to-equity of about 0.30 and equity of 481.5M against 760.5M of assets provide a relatively supportive funding base. Moderate leverage gives Egetis flexibility to finance development while pursuing profitability.
Gross Margin RecoveryTTM gross margin recovered to about 14% from very negative levels in 2022–2023. The improvement suggests product economics have become less adverse and could support future scaling, although the margin remains modest.
Bears Say
Severe Cash BurnOperating cash flow of -300.3M and free cash flow of -301.3M show that operations are not self-funding. Continued burn can require external financing, constrain development flexibility and increase funding risk.
Deep Operating LossesOperating and net margins remain roughly -5.7x to -5.9x revenue despite higher sales. Costs remain far above the revenue base, leaving limited evidence of operating leverage and making profitability dependent on substantial improvement.
Equity Erosion RiskTTM ROE of approximately -1.23 reflects losses that can erode the sizable equity base over time. If earnings do not improve, balance-sheet support may weaken and reduce financial flexibility despite moderate leverage.
Egetis Therapeutics AB News
EGTX FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was kr3.63 and its highest was kr8.15 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is kr3.72B.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Aug 21, 2026. The company reported -kr0.2 earnings per share for the quarter, missing the consensus estimate of -kr0.15 by -kr0.05.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.2.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -kr0.2 in its last earnings report, missing expectations of -kr0.15. Following the earnings report the stock price went up 7.794%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in SE:EGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
EGTX Stock 12 Month Forecast
Average Price Target
kr23.00